Navigation Links
Abbott 2009 Global Citizenship Report Highlights Company's Progress in 'Redefining Responsibility'
Date:5/6/2010

its industry sector in 2010, in part for the company's strong performance in social responsibility.

About Abbott's 2009 Global Citizenship Report

Abbott's full report of its 2009 Global Citizenship approach and performance is available online at http://www.abbott.com/citizenship, including a copy of the company's Global Reporting Initiative G3 index.  In order to reduce its environmental impact, Abbott produces a shortened printed Global Citizenship Summary Report, which provides an overview of the full information available on Abbott's Web site.  The abbreviated print version can be downloaded from the Web site.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics.  The company employs approximately 83,000 people and markets its products in more than 130 countries.  Abbott's news releases and other information are available on the company's Web site at www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... PARIS , July 30, 2014  Regeneron Pharmaceuticals, ... SAN and NYSE: SNY ) today announced ... in people with hypercholesterolemia met their primary efficacy endpoint ... lipoprotein cholesterol (LDL-C) at 24 weeks compared to placebo ... targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
(Date:7/30/2014)... July 30, 2014   Bluegrass Vascular Technologies ... innovating lifesaving devices and methods for vascular access, ... Series A financing, which was led by ... deal will allow Bluegrass Vascular to obtain CE ... enhance manufacturing capabilities, and proceed with US regulatory ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
... July 27, 2011 Pharmaceutics International, Inc. (Pii), a ... it has added hot melt extrusion (HME) to its ... has purchased a 16mm and an 18mm Leistritz twin ... feasibility studies, using just a few grams of active ...
... Pharmaceuticals, Inc., announced today that the company has ... Angel Investors. The company is using the capital ... orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for ... arthritis, multiple sclerosis, psoriasis and COPD. ...
Cached Medicine Technology:Pharmaceutics International, Inc. (Pii) Expands Drug Formulation and Manufacturing Capabilities with Hot Melt Extrusion Technology 2Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities 2
(Date:7/30/2014)... 2014 Decene is an alkene ... of ten carbon atoms with one double bond. ... 1-decenes. It can be used as a co-monomer ... produce epoxides, amines, oxo alcohols, synthetic lubricants, synthetic ... buyers will receive 10% customization on this report. ...
(Date:7/30/2014)... Naomi Fried, PhD, and Alexis Gilroy, ... of the American Telemedicine Association (ATA). The ... a mission to promote professional, ethical and equitable ... technology. , “Both Naomi Fried and Alexis Gilroy, ... and are well known experts in their respective ...
(Date:7/30/2014)... (HealthDay News) -- Clues to whether a person is at ... a new study suggests. Chemical changes to a gene ... spur suicidal thoughts and behaviors, the study,s authors explained. Spotting ... to a patient,s risk for suicide, they said. "Suicide ... been stymied in our prevention efforts because we have no ...
(Date:7/30/2014)... The global digital pathology market was valued at ... grow at a CAGR of 11.8%, to reach an estimated ... is growing and is expected to continue to rise in ... image analysis software enable pathologists to be efficient and this ... the North American market was valued at $128.9 million and ...
(Date:7/30/2014)... release is available in French . ... by Claude Gronfier (Inserm Unit 846: Stem Cell and ... study under real conditions on the body clocks of ... researchers have shown that a particular kind of artificial ... are correctly synchronised despite the absence of sunlight. The ...
Breaking Medicine News(10 mins):Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:American Telemedicine Association Welcomes Two New Members to the Board of Directors 2Health News:Could a Blood Test Predict Suicide Risk? 2Health News:Could a Blood Test Predict Suicide Risk? 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Dimly lit working environments: Correcting your body clock is possible! 2Health News:Dimly lit working environments: Correcting your body clock is possible! 3Health News:Dimly lit working environments: Correcting your body clock is possible! 4
... Minister Frank Nweke has said in a statement that a ... states//, and one among them is Nigeria’s southern most state. ... the central state of Benue and Port Harcourt in Rivers ... virus. According to Frank, "The culling of infected birds and ...
... treatment of erectile dysfunction or impotence can now be ... disease//. Pfizer, a leading pharmaceutical company, is marketing the ... ,The drug approved for use in last ... the same active ingredients as the pill, Viagra. The ...
... Unilever has announced a partnership with the World Dental ... Middle East and Turkey.// Both organizations will assist National ... spread awareness about the importance of oral health. ... Learn. Laugh. The programs include school education programmes and ...
... Researchers at the University of Illinois at Urbana-Champaign ... nanoparticles to produce new drug and agricultural materials ... materials science and engineering, chemistry and physics said ... hollow, deformable and biofunctional capsules could be used ...
... governor of South Dakota signed a law banning abortions, which ... and also which may trigger national debate. // ... Supreme Court decision, known as Roe vs. Wade, that made ... abortion. ,Governor Mike Rounds, a member of President ...
... back slowly after its steep fall from grace, following the ... bies and on the house access to chicken delicacies have ... onto people’s plates. ,The farm-gate prices had recorded ... 1.20 while the chicken prices had hit rock bottom at ...
Cached Medicine News:Health News:Medical Boon in the Form of a Biofriendly Capsule 2
... Guide 2005 includes over 1,000 commonly used ... their selection and administration. Organized alphabetically by ... key data featuring common uses and side ... patient education information. A list of the ...
... Drugs is a dynamic new mobile ... easy to check on the compatibility ... selected drugs, clear compatibility and stability ... quickly take clinical action based on ...
Providing patients and their advocates with a variety of information services and educational materials on clinical research....
... DrDrugs®: Drug Guide ... with over 760 Integrated ... most comprehensive, up-to-date and ... built in drug dosing ...
Medicine Products: